Otonomy, Inc. (OTIC)
Stock Price:
$4.57 USD
0.27 (6.28%)
Updated November 27, 12:46 PM EST - Market open
Key Info
| Market Cap |
220.40M |
| Revenue (ttm) |
313,000 |
| Net Income (ttm) |
-45.01M |
| Shares Out |
48.23M |
| EPS (ttm) |
-1.27 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 27 |
| Last Price |
$4.57 |
| Previous Close |
$4.30 |
| Change ($) |
0.27 |
| Change (%) |
6.28% |
| Day's Open |
4.29 |
| Day's Range |
4.26 - 4.63 |
| Day's Volume |
157,719 |
| 52-Week Range |
1.53 - 4.89 |
More Stats
| Market Cap |
220.40M |
| Enterprise Value |
157.83M |
| Earnings Date (est) |
Mar 8, 2021 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
48.23M |
| Float |
43.73M |
| EPS (basic) |
-1.32 |
| EPS (diluted) |
-1.27 |
| FCF / Share |
-0.78 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
620,893 |
| Short Ratio |
3.52 |
| Short % of Float |
1.42% |
| Beta |
2.16 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
704.16 |
| PB Ratio |
2.81 |
| Revenue |
313,000 |
| Operating Income |
-44.04M |
| Net Income |
-45.01M |
| Free Cash Flow |
-38.38M |
| Net Cash |
62.57M |
| Net Cash / Share |
1.30 |
| Gross Margin |
-99.68% |
| Operating Margin |
-14,070.93% |
| Profit Margin |
-14,379.90% |
| FCF Margin |
-12,261.98% |
| ROA |
-26.55% |
| ROE |
-71.59% |
| ROIC |
-64.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (5)
| Buy |
5 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$10.00*
(118.82% upside)
Low
9.00
Current: $4.57
High
11.00
Target: 10.00
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | 0.60 | 0.75 | 1.24 | 0.68 | - | - | - | - |
| Revenue Growth | -19.46% | -39.72% | 80.97% | - | - | - | - | - |
| Gross Profit | -0.31 | -0.20 | -1.86 | -0.98 | - | - | - | - |
| Operating Income | -44.81 | -52.05 | -91.40 | -111 | -61.98 | -39.64 | -19.85 | -10.93 |
| Net Income | -44.68 | -50.37 | -90.13 | -111 | -61.67 | -42.88 | -19.56 | -7.57 |
| Shares Outstanding | 30.73 | 30.61 | 30.30 | 29.96 | 23.95 | 7.85 | 0.07 | 0.07 |
| Earnings Per Share | -1.45 | -1.65 | -2.97 | -3.69 | -2.57 | -5.46 | -268.79 | -118.99 |
| Operating Cash Flow | -36.93 | -38.43 | -75.31 | -94.31 | -49.90 | -35.22 | -19.47 | -10.83 |
| Capital Expenditures | -0.70 | -0.50 | -1.26 | -2.55 | -2.02 | -0.78 | -0.49 | -0.19 |
| Free Cash Flow | -37.63 | -38.93 | -76.57 | -96.85 | -51.92 | -36.00 | -19.95 | -11.01 |
| Cash & Equivalents | 61.37 | 97.98 | 121 | 197 | 186 | 156 | 37.36 | 4.71 |
| Total Debt | 33.59 | 14.76 | - | - | - | - | - | 7.07 |
| Net Cash / Debt | 27.78 | 83.22 | 121 | 197 | 186 | 156 | 37.36 | -2.35 |
| Assets | 83.02 | 105 | 128 | 209 | 193 | 159 | 39.76 | 5.90 |
| Liabilities | 42.79 | 25.26 | 11.09 | 15.86 | 11.50 | 5.55 | 3.58 | 11.92 |
| Book Value | 40.23 | 79.74 | 117 | 193 | 182 | 154 | -58.98 | -39.07 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Otonomy, Inc. |
| Country |
United States |
| Employees |
49 |
| CEO |
David A. Weber |
Stock Information
| Ticker Symbol |
OTIC |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: OTIC |
| IPO Date |
August 13, 2014 |
Description
Otonomy, a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of Ménière's disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase I/II clinical trial to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase I/II clinical trial for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. In addition, the company develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; and OTO-6XX induces hair cell regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was founded in 2008 and is headquartered in San Diego, California.